Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Revenue (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Revenue for 5 consecutive years, with $80.0 million as the latest value for Q2 2024.

  • Quarterly Revenue rose 8990.91% to $80.0 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $80.0 million through Mar 2025, up 3087.25% year-over-year, with the annual reading at $80.0 million for FY2024, 2752.05% up from the prior year.
  • Revenue for Q2 2024 was $80.0 million at Fulcrum Therapeutics, up from $871000.0 in the prior quarter.
  • The five-year high for Revenue was $80.0 million in Q2 2024, with the low at $295000.0 in Q1 2023.
  • Average Revenue over 5 years is $6.9 million, with a median of $1.9 million recorded in 2022.
  • The sharpest move saw Revenue plummeted 88.62% in 2023, then skyrocketed 8990.91% in 2024.
  • Over 5 years, Revenue stood at $4.2 million in 2020, then grew by 19.72% to $5.1 million in 2021, then tumbled by 86.46% to $685000.0 in 2022, then rose by 27.15% to $871000.0 in 2023, then surged by 9084.85% to $80.0 million in 2024.
  • According to Business Quant data, Revenue over the past three periods came in at $80.0 million, $871000.0, and $759000.0 for Q2 2024, Q4 2023, and Q3 2023 respectively.